Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer

Fig. 2

Prognostic value of MTOR in CRC patients. A, B Kaplan–Meier survival curve comparing high (N = 279) and low (N = 280) MTOR expression determined by the median value and high (N = 140) and low (N = 140) MTOR expression determined by quantile value for the TCGA CRC patient cohort. C, D Kaplan–Meier survival curve comparing high (N = 95) and low (N = 96) MTOR expression determined by the median value and high (N = 47) and low (N = 47) MTOR expression determined by quantile value for the CRC patients in the GSE87211 database. CRC, colorectal cancer; TCGA, The Cancer Genome Atlas

Back to article page